0000950170-23-068812.txt : 20231207
0000950170-23-068812.hdr.sgml : 20231207
20231207161505
ACCESSION NUMBER: 0000950170-23-068812
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231205
FILED AS OF DATE: 20231207
DATE AS OF CHANGE: 20231207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bryce Joanne
CENTRAL INDEX KEY: 0001951845
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 231472546
MAIL ADDRESS:
STREET 1: C/O DISC MEDICINE, INC.
STREET 2: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Disc Medicine, Inc.
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 674-9274
MAIL ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE
DATE OF NAME CHANGE: 20210209
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
ownership.xml
4
X0508
4
2023-12-05
0001816736
Disc Medicine, Inc.
IRON
0001951845
Bryce Joanne
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101
WATERTOWN
MA
02472
false
true
false
false
Chief Financial Officer
true
Common Stock
2023-12-05
4
M
false
526
1.01
A
4286
D
Common Stock
2023-12-05
4
M
false
755
1.01
A
5041
D
Common Stock
2023-12-05
4
S
false
1148
55.2947
D
3893
D
Common Stock
2023-12-05
4
S
false
1293
56.5466
D
2600
D
Common Stock
2023-12-05
4
S
false
100
57.0600
D
2500
D
Stock Option (Right to Buy)
1.01
2023-12-05
4
M
false
526
0.00
D
2029-11-05
Common Stock
526
0
D
Stock Option (Right to Buy)
1.01
2023-12-05
4
M
false
755
0.00
D
2029-11-05
Common Stock
755
752
D
The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.93 to $55.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.05 to $57.04, inclusive.
The shares underlying this option are fully vested and exercisable as of the date hereof.
The shares underlying this option vest in 16 equal quarterly installments following May 1, 2020, subject to the Reporting Person's continued service on each such vesting date.
By: /s/ Rahul Khara, as Attorney-in-Fact
2023-12-07